 |
|
Adverse Events Related to Muraglitazar Use in Diabetes—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Najman and Dr Parra and colleagues raise important and valid concerns about dual PPAR agonists. Both letters recommend caution in the coadministration of fibric acid derivatives and thiazolidinediones, a strategy that would activate both PPAR- and  receptors via 2 separate agents. Najman points out that some studies using the older PPAR- agents gemfibrozil and bezafibrate showed nonsignificant increases in mortality. In addition, the recent Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study showed a 19% higher mortality rate in the fenofibrate treatment group (P = .22).1 In the muraglitazar analyses, we could not assess the impact of coadministration of the approved fibric acid derivatives because these agents were prohibited in the study designs.2-3
Both letters suggest that morbidity and mortality trials are needed before approval of new therapeutic classes to be used in high-risk populations, such as patients with diabetes. I would disagree with such a . . . [Full Text of this Article]
Steven E. Nissen, MD
nissens@ccf.org
Department of Cardiovascular Medicine
Cleveland Clinic Foundation
Cleveland, Ohio
RELATED ARTICLES
Adverse Events Related to Muraglitazar Use in Diabetes
David M. Najman
JAMA. 2006;295(17):1997.
EXTRACT
| FULL TEXT
Adverse Events Related to Muraglitazar Use in Diabetes
David Parra, Cherylyn Beckey, and Thomas Thomas
JAMA. 2006;295(17):1997-1998.
EXTRACT
| FULL TEXT
Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Steven E. Nissen, Kathy Wolski, and Eric J. Topol
JAMA. 2005;294(20):2581-2586.
ABSTRACT
| FULL TEXT
|
